Dr Janice Reichert | Executive Director
The Antibody Society

Dr Janice Reichert, Executive Director, The Antibody Society

Dr. Janice Reichert is an internationally-recognized expert in the development of antibody therapeutics. She is Executive Director of The Antibody Society, a non-profit association representing individuals and organizations that engage in antibody research or development. Dr. Reichert is also Founder and Editor-in-Chief of mAbs, a peer-reviewed, PubMed-indexed biomedical journal that focuses on topics relevant to antibody research and development, and Founder and Managing Director of Reichert Biotechnology Consulting LLC, a pharmaceutical business intelligence research firm. Dr. Reichert writes frequently on development trends for antibody therapeutics, including the annual ‘Antibodies to watch’ articles published in mAbs, and she has presented her research results as an invited speaker at conferences held worldwide.


EAC 2017 Day 3, Thursday 2nd November 2017 @ 15:25

Antibodies to watch in 2018

  • A new record (14) for recombinant antibody products granted first marketing approvals may be set in 2017. These products, and those that might be granted approvals in 2018, will be identified.  
  • Antibody therapeutics in Phase 3 clinical studies will be discussed, and those likely to move to regulatory review in 2018 will be noted. 
  • New data on antibody therapeutics development metrics, including clinical phase transition and approval success rates, will be presented.

back to speakers